NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma.

Pooja A Shah, Chenfei Huang, Qiuli Li, Sawad A Kazi, Lauren A Byers, Jing Wang, Faye M Johnson, Mitchell J Frederick

Cells 2020 Dec 12

filter terms:

Biomarker-driven targeted therapies are lacking for head and neck squamous cell carcinoma (HNSCC), which is common and lethal. Efforts to develop such therapies are hindered by a genomic landscape dominated by the loss of tumor suppressor function, including NOTCH1 that is frequently mutated in HNSCC. Clearer understanding of NOTCH1 signaling in HNSCCs is crucial to clinically targeting this pathway. Structural characterization of NOTCH1 mutations in HNSCC demonstrates that most are predicted to cause loss of function, in agreement with NOTCH1's role as a tumor suppressor in this cancer. Experimental manipulation of NOTCH1 signaling in HNSCC cell lines harboring either mutant or wild-type NOTCH1 further supports a tumor suppressor function. Additionally, the loss of NOTCH1 signaling can drive HNSCC tumorigenesis and clinical aggressiveness. Our recent data suggest that NOTCH1 controls genes involved in early differentiation that could have different phenotypic consequences depending on the cancer's genetic background, including acquisition of pseudo-stem cell-like properties. The presence of NOTCH1 mutations may predict response to treatment with an immune checkpoint or phosphatidylinositol 3-kinase inhibitors. The latter is being tested in a clinical trial, and if validated, it may lead to the development of the first biomarker-driven targeted therapy for HNSCC.

Citation

Pooja A Shah, Chenfei Huang, Qiuli Li, Sawad A Kazi, Lauren A Byers, Jing Wang, Faye M Johnson, Mitchell J Frederick. NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma. Cells. 2020 Dec 12;9(12)